ACL.AX ASX
Australian Clinical Labs Limited
1W: +0.7%
1M: +3.0%
3M: +22.4%
YTD: +11.2%
1Y: +6.9%
3Y: +3.7%
5Y: -21.2%
A$2.81 ($1.95)
+0.02 (+0.72%)
Weekly Expected Move ±3.4%
A$3
A$3
A$3
A$3
A$3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$163M
-10.7% ▼
5Y CAGR: +1.2%
Capital Expenditures
$10M
-13.9% ▼
5Y CAGR: +0.1%
Free Cash Flow
$154M
-11.8% ▼
5Y CAGR: +1.3%
Dividends Paid
$25M
+1.4% ▲
Buybacks
$23M
-21.1% ▼
Net Change in Cash
$3M
+170.1% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $178M | $36M | $24M | $32M | $24M |
| Depreciation & Amort. | $106M | $123M | $128M | $136M | $135M |
| Stock-Based Comp. | $1M | $2M | $3M | $3M | $0 |
| Change in Working Capital | -$11M | -$6M | $487K | $9M | $12M |
| Other Non-Cash Items | $10M | -$9M | $4M | $1M | -$8M |
| Operating Cash Flow | $284M | $144M | $160M | $183M | $163M |
| — Investing Activities — | |||||
| Capital Expenditures | -$21M | -$7M | -$7M | -$8M | -$10M |
| Acquisitions (Net) | -$51M | -$5M | -$1M | -$583K | $299K |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $0 | $0 | $325K | $99K | $0 |
| Investing Cash Flow | -$72M | -$12M | -$7M | -$9M | -$9M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$100M | $66M | -$11M | -$135M | $20M |
| Stock Repurchased | -$5M | -$891K | -$2M | -$19M | -$23M |
| Dividends Paid | -$24M | -$97M | -$20M | -$25M | -$25M |
| Other Financing | -$92M | -$106M | -$113M | $0 | -$123M |
| Financing Cash Flow | -$221M | -$138M | -$146M | -$179M | -$151M |
| Net Change in Cash | -$9M | -$6M | $6M | -$5M | $3M |
| Cash End of Period | $26M | $20M | $26M | $21M | $25M |
| Free Cash Flow | $263M | $137M | $153M | $174M | $154M |